Dickkopf-1 (DKK1) promotes tumor growth via Akt-phosphorylation and independently of Wnt-axis in Barrett’s associated esophageal adenocarcinoma by Lyros, Orestis et al.
Am J Cancer Res 2019;9(2):330-346
www.ajcr.us /ISSN:2156-6976/ajcr0083189
Original Article
Dickkopf-1 (DKK1) promotes tumor growth via  
Akt-phosphorylation and independently of Wnt-axis  
in Barrett’s associated esophageal adenocarcinoma
Orestis Lyros1*, Ann-Kristin Lamprecht1*, Linghui Nie2, René Thieme1, Katharina Götzel1, Mario Gasparri3, 
George Haasler3, Parvaneh Rafiee4, Reza Shaker2, Ines Gockel1
1Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital, Leipzig, Germany; 
2Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; 3Division 
of Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; 4Department of Surgery of 
Medical College of Wisconsin, Milwaukee, Wisconsin, USA. *Equal contributors.
Received July 27, 2018; Accepted November 24, 2018; Epub February 1, 2019; Published February 15, 2019
Abstract: Esophageal adenocarcinoma (EAC) is still associated with poor prognosis, despite modern multi-modal 
therapies. New molecular markers, which control cell cycle and promote lymph node metastases or tumor growth, 
may introduce novel target therapies. Dickkopf-1 (DKK1) is a secreted glycoprotein that blocks the oncogenic Wnt/
β-catenin signaling and its aberrant expression has been observed in many malignancies, including EAC. In this 
study, we investigated the biological role of DKK1 in EAC. Analysis of DKK1 and active β-catenin expression in 
human esophageal tissues confirmed a simultaneous DKK1-overexpression together with aberrant activation of 
β-catenin signaling in EAC in comparison with Barrett’s and healthy mucosa. To elucidate the molecular role of 
DKK1, the OE33 adenocarcinoma cells, which were found to overexpress DKK1, were subjected to functional and 
molecular assays following siRNA-mediated DKK1-knockdown. At the functional level, OE33 cell viability, prolifera-
tion, migration and invasion were significantly attenuated by the absence of DKK1. At the molecular level, neither 
DKK1-knockdown nor application of exogenous recombinant DKK1 were found to alter the baseline β-catenin sig-
naling in OE33 cells. However, DKK1-knockdown significantly abrogated downstream Akt-phosphorylation. On the 
other hand, the Wnt-agonist, Wnt3a, restored the Akt-phorphorylation in the absence of DKK1, without, however, 
being able to further stimulate β-catenin transcription. These findings suggest that the β-catenin transcriptional ac-
tivity in EAC is independent of Wnt3a/DKK1 site-of-action and define an oncogenic function for DKK1 in this type of 
malignancy via distinct activation of Akt-mediated intracellular pathways and independently of Wnt-axis inhibition. 
Taken together, DKK1 may present a novel therapeutic target in EAC. 
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Introduction
The incidence of esophageal adenocarcinoma 
(EAC) has been rapidly increased in the western 
world over the last decades [1] and its develop-
ment has been associated with Barrett’s eso- 
phagus (BE), which is the replacement of nor-
mal squamous epithelium of the distal esopha-
gus by metaplastic columnar mucosa in respon- 
se to chronic gastroesophageal reflux disease 
(GERD) [2]. Radical surgical resection of the es- 
ophagus offers the best treatment option for 
EAC-patients while the addition of neodjuvant 
chemo (radio) therapy has improved survival 
rates [3]. However, the prognosis of EAC still 
remains unfavorable, with 5-year survival less 
than 15%, due to local recurrence and early re- 
gional or systemic metastases [4]. EAC-patients 
might further benefit from addition of other 
forms of therapies, such as molecular therapy, 
which specific targets biological markers that 
have a prominent role in cell cycle control pro-
gression, lymph node metastases and tumor 
progression. Identification of such novel targets 
requires understanding of the molecular mech-
anisms underlying the EAC tumor biology, which 
still remains largely undefined. 
The Wnt-signaling cascade orchestrates a wide 
variety of biological processes during embryon-
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ic development and tissue homeostasis, such 
as cell division, proliferation or differentiation, 
while its dysregulation has been tightly associ-
ated with cancer [5]. Wnt-signaling is either 
canonical or non-canonical based on the role 
played by the effector protein β-catenin [6]. 
Activation of the canonical Wnt/β-catenin sig-
naling is marked by nuclear translocation of 
β-catenin in the presence of secreted Wnt gly-
coproteins or different mitotic signals. In the 
absence of Wnt-signal, β-catenin is seques-
tered in a “destruction complex”, consisting of 
glycogen synthase kinase-3β (GSK-3β), casein 
kinase 1 (CK1), adenomatous polyposis coli 
(APC) and Axin [7]. This complex forces the 
phosphorylation of β-catenin, which then is 
subjected to subsequent degradation by the 
ubiquitin-proteasome system [7]. Upon Wnt-
signal, β-catenin is dephosphorylated and ac- 
cumulates in the cytoplasm and subsequently 
to the nucleus, where it binds to members of 
the TCF/LEF-1 transcription factors and initi-
ates transcription of target genes (Cyclin D1, 
Axin2, c-MYC, DKK1, etc.) [8]. 
During the neoplastic progression of BE to- 
wards EAC, an increased nuclear accumula- 
tion of β-catenin has been reported, signifying 
an aberrant activation of Wnt-signaling in EAC 
[9-11]. Intriguingly, the common genetic altera-
tions of Wnt-signaling components, such as 
β-catenin, APC and Axin, are not frequently 
detected in EAC similarly to other human malig-
nancies [12]. Instead, EAC is marked by chang-
es, such as loss of the negative regulators of 
the pathway, such as the Wnt inhibitory factor 1 
(WIF) or the secreted frizzled receptor proteins 
(SFRPs), along with induction of Wnt-2 expres-
sion, which together are expected to increase 
signaling along the WNT axis [12, 13]. However, 
the underlying mechanism of increased Wnt/β-
catenin signaling in EAC and its impact in tumor 
biology needs to be explored.
Dickkopf-1 (DKK1) is a secreted glycoprotein, 
which specifically antagonizes the oncogenic 
canonical Wnt/β-catenin signaling, by binding 
onto the extracellular domain of the Wnt co-
receptor LRP-6 (Low density lipoprotein recep-
tor-related protein 6), thus preventing the Wnt-
induced stabilization of β-catenin [14]. At the 
transcriptional level, DKK1 is a direct target of 
the β-catenin/T-cell factor (TCF) complex, sug-
gesting a negative feedback loop in Wnt-sig- 
naling regulation [15, 16]. Dysregulation in any 
step of the Wnt/β-catenin signaling cascade, 
including DKK1 mediated repression, leads to 
numerous developmental abnormalities and 
diseases, with the most widely studied being 
cancer [17]. Several studies reported downreg-
ulation or silenced DKK1-expression in intesti-
nal cancers [15, 18], supporting that DKK1 
functions as tumor suppressor, via inhibition of 
the oncogenic Wnt-signaling [19]. Then again, 
DKK1-overexpression has been detected and 
correlated with poor survival in diverse malig-
nancies, such as multiple myeloma, non-small 
cell lung cancer, urothelial carcinoma, bladder 
cancer, gynaecological cancer and hepatocel-
lular carcinoma (HCC), suggesting that DKK1 
could promote tumor growth [17, 20]. Charac- 
teristically, DKK1-upregulation in gastric can- 
cer correlated with tumor invasion [21]. In BE- 
dysplasia and mainly in EAC, elevated DKK1-
expression has been previously reported [22, 
23]. Interestingly, DKK1 was found to suppress 
β-catenin signaling in Barrett-metaplastic cells 
(CP-A) in vitro, supporting that an early pertur-
bation of DKK1-mediated suppression of Wnt-
axis may contribute to EAC-tumorigenesis [23]. 
In line with tumor progression, lymph node 
metastasis in EAC was found to correlate with 
high levels of DKK1 in the loco-regional lymph 
nodes of the primary tumor [24], proposing that 
DKK1 tumor secretion may orchestrate lym-
phatic metastasis. Taken together, these ran-
dom observations so far propose a key role 
for DKK1 in the EAC, which merits further 
clarification.
The present study was undertaken to explore 
the molecular role of DKK1 in EAC tumor biolo-
gy with regard to (a) tumor cell proliferation and 
invasion as well as (b) modulation of tumorigen-
ic intracellular pathways, including the canoni-
cal Wnt/β-catenin signaling, the common intra-
cellular tyrosine kinases activation and the epi- 
thelial-mesenchymal transition (EMT). By ana-
lyzing esophageal cell lines in vitro, we provide 
evidence supporting that DKK1 functions as a 
tumor promoter in EAC by inducing tumor cell 
proliferation and invasion. Intriguingly, this DK- 
K1-mediated tumor promotion in EAC cells 
was found to be independent of the Wnt-axis, 
but via activation of Akt-mediated intracellular 
pathways. These novel findings underscore the 
significance of DKK1 as a potential therapeutic 
target in EAC and provide new insights into the 
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Human esophageal specimens were collected 
from patients with EAC following surgical eso- 
phagectomy without previous neo-adjuvant tre- 
atment. Studies were approved by the Human 
Research Review Committee of the Medical 
College of Wisconsin, and study participants 
gave written informed consent prior to their 
studies. 
Cell culture
Human squamous esophageal telomerase-im- 
mortalized cells EPC1-hTERT (EPC1) and EPC2-
hTERT (EPC2) were the generous gifts of Dr. 
Hiroshi Nakagawa, Gastroenterology Division, 
University of Pennsylvania, USA and were 
grown as previously described [25]. The non-
dysplastic columnar cell line CP-A (CRL-4027) 
and the high-grade dysplastic columnar cell 
line CP-B (CRL-4028) were obtained from the 
American Type Culture Collection (Rockville, 
MD) and were grown in MCDB-135 Basal Me- 
dium (Biochrom, Berlin, Germany) supplement-
ed according to the manufacturer’s protocol. 
Esophageal adenocarcinoma cell lines OE33 
(ECACC-96070808) and OE19 (ECACC-96071- 
721) purchased from Sigma Aldrich (Taufkir- 
chen, Germany) were adapted to RPMI 1640 
growth medium (Gibco, Waltham, USA) supple-
mented with 10% bovine serum (Biochrom, 
Berlin, Germany). All cell lines were preserved 
optimally at 37°C in humidified air with 5% CO2 
until confluency reached 80% to 90%.
Reagents and antibodies
Recombinant human DKK1 (rhDKK1), recombi-
nant human Wnt3a (rhWnt3a), as well as re- 
combinant human VEGF (rhVEGF) were obtain- 
ed from R&D Systems Inc. (Minneapolis, MN). 
Primary antibodies were used against DKK1 
(Abcam, Cambridge, MA), LRP6 (R&D Systems 
Inc.), p53 (Millipore, Billerica, MA), Caspase 3 
(BD Transduction Laboratories Biosciences), 
E-Cadherin (Novus Biochemicals) and β-actin 
(Sigma Aldrich, St. Louis, MO). Other primary 
antibodies against β-catenin, Phospho-GSK3β 
(Ser9), GSK3β, Phospho-Akt (Ser473), Akt, Ph- 
ospho-Erk1/2 (Thr202/Tyr204), Erk1/2 and 
Bcl-xL were obtained from Cell Signaling Te- 
chnology (Danvers, MA). Horseradish peroxi-
dase-conjugated secondary antibodies were 
purchased from Jackson Immuno Research 
Laboratories Inc. (West Grove, PA). All other 
reagents and chemicals were obtained either 
from Sigma Aldrich (Taufkirchen, Germany) or 
CarlRoth (Karlsruhe, Germany) unless other-
wise indicated.
RNA isolation and cDNA synthesis 
RNA was isolated from cell cultures using Qia- 
gen RNeasy Mini Kit (Valencia, CA) according to 
the manufacturer’s protocol. cDNA preparation 
was performed with Revert Aid Kit purchased 
from Thermo Fisher Scientific (Waltham, MA). 
The cDNA probes were synthesized from one 
microgram of total RNA.
Quantitative polymerase chain reaction (qRT-
PCR) 
RT-PCR was performed with DreamTaq Green 
PCR Master Mix (ThermoFisher Scientific, Wal- 
tham, MA) by adding 1 μl primer, 0.5 μl (β-actin 
primer) and 2 μl (Dkk1 primer) of cDNA per 
20-μl reaction, respectively. Gel electrophore-
sis for fractionation of the nuclear acids was 
performed with 1.5% agarose gels. qRT-PCR 
was performed in 20-μl reaction, 1 μl primer 
and 1 μl cDNA were added to the fluoresced 
SYBR-Green Master-Mix (Thermo Fisher Scien- 
tific) and gene expression was analyzed with 
RotorGene Anaysis Software (Qiagen Corbett 
Research). Relative quantification to reference 
gene β-actin was calculated with the ΔΔCt-




CGCAACTAAGTCATAG], Axin2 [Forward-CCACT- 
GGCCGATTCTTCCTT, Reverse-TACCGGAGGATG- 
CTGAAGGC], Cyclin-D1 [Forward-GGCGGATTG- 
GAAATGAACTT, Reverse-TCCTCTCCAAAATGCC- 
AGAG] were obtained from Sigma Aldrich 
(Taufkirchen, Germany).
Western blot analysis
Cell lysis, protein extraction and western blot 
analysis was performed as previously described 
[23].
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ELISA
DuoSet Ancillary Reagent Kit and the corre-
sponding Human Dkk-1 DuoSet ELISA were 
obtained from R&D Systems Inc. (Minneapolis, 
MN). Cell culture supernatants were diluted at 
a ratio 1:3 in 1% BSA in bovine serum and 
ELISA was performed according to the manu-
facturer’s protocol.
Dkk1 gene silencing
Transfection of OE33 cells (60%-70% conflu-
ence) was performed with specific short inter-
fering RNAs (siRNAs) targeting either human 
DKK1 (target gene) (ON-TARGET plus SMART 
pool, Human-DKK1 (22943), Dharmacon, Lafa- 
yette, CO) or GAPDH-siRNA (positive control) 
(human ON-TARGETplus GAPDH Control siRNA, 
Dharmacon) with DharmaFECT transfection re- 
agent. Non-targeting-siRNAs (ON-TARGETplus 
Non-targeting siRNA, Dharmacon) were used 
as a negative control. All reagents were used 
according to the manufacturer’s protocol (Dh- 
armacon), resulting in a final siRNA concentra-
tion of 25 nM. 
Cellular assays
Proliferation was assessed by 3-(4,5-dimeth- 
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay and 3H-thymidine incorporation 
assay. For MTT assays, OE33 cells were seed-
ed in 96-well plates. If not treated with rhDkk1 
(500 ng/ml) or rhWnt3a (200 ng/ml), Dkk1 ge- 
ne silencing was performed and MTT-measure- 
ments were conducted in six-fold replicates at 
the time 0 h, 48 h, 72 h, 96 h, 120 h and 144 h 
following siRNA transfection by adding MTT 
stock solution (5 mg/ml in bovine serum) to the 
wells. Thus, time of treatment represents 0 h. 
After 3 hours of incubation at 37°C, MTT stop-
solution (sodiumdodecylsulfate (5.87 M) in 
50% dimethylformamide solution) was added 
and absorption at 560 nm was measured after 
24 hours by Spektramax M5 (Molecular Devi- 
ces, Sunnyvale, CA). 3H-thymidine incorporation 
assay was performed as previously described 
[25]. 
Motility/migration was determined by wound 
healing assays by placing OE33 cells into the 
two chambers of ibidi culture inserts (Madison, 
WI). Then, DKK1-gene silencing was performed, 
and cells were grown until confluency reached 
90%. After inserts removal, OE33 cells were 
separated through a 500 μm gap. The growth 
process over the gap was observed and docu-
mented under the microscope at certain times 
points as indicated. The gap width was quanti-
fied with ImageJ 1.48v (National Institute of 
Health, NY). 
Transmigration assay: Cells were seeded into 
the upper chamber of special 24-well plates 
(BD Biosciences, San Jose, CA) following DKK1-
Knockdown. After 48 hours of incubation, the 
cells were fluorescence stained with 4 μg/ml 
Calcein (Becton Dickson, Franklin Lakes, NJ) 
and fluorescence signal in the lower chamber 
was detected “from bottom” (405/595 nm) by 
Spektramax M5.
Luciferase reporter assay
Luciferase assay using DNA plasmids of β- 
catenin-LEF/TCF sensitive (TOP-flash) and β- 
catenin-LEF/TCF insensitive (FOP-flash) report-
er vectors (Addgene, Cambridge, MA), as well 
as Lipofectamine 2000 (Invitrogen, Carlsbad, 
CA) was performed as previously described 
[23].
Immunofluoresence & inverted microscopy
Zen lite 2012 software (Axiovert25, Zeiss, Ob- 
erkochen) was used for cell culture observa- 
tion and photography (100-fold magnification). 
Immunofluorescence was performed as previ-
ously described [23]. 
Statistical analysis
Calculation was performed using GraphPad 
Prism 5.0 analysis software. All data were ex- 
pressed as mean ± SEM. Dependent on the 
presence of a Gaussian distribution, Student’s 
t tests or Mann-Whitney tests were used to 
evaluate significant differences. Cell culture 
experiments with three independent variables 
were tested with Two-Way-Anova (Post-hoc ana- 
lysis: Bonferroni’s Multiple Comparision Test). 
P-values less than .05 were considered statis- 
tically significant.
Results
DKK1 is overexpressed in BE-associated 
esophageal adenocarcinoma cells
We have previously reported that DKK1 expres-
sion is higher in BE and even higher in EAC, 
when compared to that of the corresponding 
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Figure 1. DKK1 expression in esophageal squamous mucosa, Barrett’s metaplasia and esophageal adenocarci-
noma: A. Immunofluorescence microscopy for expression and co-localization of DKK1 and ABC protein in squamous 
esophageal mucosa (SQ), non-dysplastic Barrett’s metaplasia (BE) and esophageal adenocarcinoma (EAC). Repre-
sentative tissue staining of at least three different tissues is presented. B. RT-PCR (a) and qRT-PCR (b) analysis of 
DKK1 mRNA expression in two squamous esophageal cell lines (EPC1/EPC2), two BE metaplasia cell lines (CP-A; 
nondysplastic/CP-B; high grade dysplasia), one barrett-associated esophageal adenocarcinoma cell line (OE33) 
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healthy squamous mucosa (SQ) in human es- 
ophageal specimens ex vivo by using immuno-
histochemistry [23]. Given that DKK1 counter-
acts the Wnt/β-catenin signaling as a specific 
Wnt-inhibitor, we were firstly interested to re- 
veal, how DKK1-expression correlates with β- 
catenin signaling activation in EAC-tissue. By 
using a specific antibody that detects the 
amounts of the dephosphorylated β-catenin, 
specifically at Ser37/Thr41, which is not sus-
ceptible to ubiquitination and degradation, and 
its cytoplasmic/nuclear amounts are consid-
ered to be highly transcriptionally active (ABC) 
[26], we co-stained human esophageal speci-
mens for DKK1- and ABC-protein expression. 
As shown by fluorescence microscopy (Figure 
1A), DKK1-protein demonstrated a reverse 
pattern of expression with that of ABC in SQ, 
while high levels of DKK1-protein co-existed 
with elevated nuclear and cytoplasmatic ABC-
expression in EAC compared to BE, favoring a 
failure of DKK1 to negatively regulate the tran-
scriptionally active β-catenin in cancer cells as 
in normal squamous cells. 
To further elucidate the molecular role of DKK1 
in EAC, we utilized a panel of cell lines in vitro, 
representing the sequence of the esophageal 
squamous mucosa (EPC1-, EPC2-hTERT), the 
esophageal Barrett’s metaplasia (CP-A) and 
dysplasia (CP-B) as well as the BE-associated 
esophageal adenocarcinoma (OE33) and the 
adenocarcinoma of gastric cardia/esophageal 
gastric junction (OE19) and characterized them 
on DKK1-expression. Compared to the rest of 
cell lines, OE33 cancer cells demonstrated 
significantly higher DKK1-mRNA levels (P < 
0.0001) (Figure 1Ba, 1Bb), as well as markedly 
elevated intracellular DKK1-protein levels (P < 
0.001) (Figure 1C), as shown by conventional 
PCR, qRT-PCR, and Western blotting respec-
tively. In contrast, OE19 cells demonstrated 
lower levels of DKK1-mRNA and protein, equiv-
alent to those of the dysplastic CP-B cells. 
These results verify an up-regulation of DKK1-
expression along the progression of squam- 
ous epithelium towards EAC. Accordingly, we 
focused on OE33 cells in our following experi-
ments in order to investigate the impact of 
DKK1 on cellular functions and molecular sig-
naling pathways.
Efficient siRNA-mediated DKK1-knockdown in 
OE33 esophageal adenocarcinoma cells
To explore the biological impact of DKK1-upre- 
gulation in EAC, we aimed to knockdown DKK1 
in OE33 cells and seek for cell function altera-
tions. Following transfection of resting OE33 
cells with small-interfering RNA against DKK1 
(DKK1-siRNA) for 48 hours, we demonstrated a 
significant decrease in DKK1-mRNA levels, over 
70% of the baseline, either by conventional 
PCR (Figure 2Aa) or qRT-PCR (Figure 2Ab). The 
efficient DKK1-knockdown was further confirm- 
ed at the protein level. The intracellular levels 
and the secreted amounts of DKK1-protein 
were significantly attenuated following DKK1-
siRNA transfection in OE33 cells, as shown by 
western blotting (Figure 2B) and ELISA (Figure 
2C) respectively. The DKK1-knockdown did not 
alter the cell morphology (Figure 2D). Notably, 
siRNA-mediated DKK1-knockdown was susta- 
ined at the protein level even after 144 hours 
following siRNA-transfection, as demonstrated 
by western blotting (Supplementary Figure 1A), 
enabling us to perform additional experimenta-
tion over this time frame. The specific knock-
down of DKK1 by DKK1-siRNA was demonstrat-
ed by using appropriate controls (GAPDH-siRNA 
as a positive control and nontargeted siRNA 
as a negative control) (Figure 2E). Thus, OE33 
cells, following efficient DKK1-knockdown, we- 
re subjected to further functional and molecu-
lar assays.
DKK-1-knockdown attenuated OE33 cell prolif-
eration and migration
We examined first the functional consequen- 
ces of DKK1-knockdown in OE33 cell growth. 
Following DKK1-knockdown, cell viability was 
significantly decreased, as measured by MTT-
assay up to 144 hours following DKK1-siRNA 
transfection (Figure 3A). To elucidate, whether 
the attenuated cell viability following DKK1-
knockdown is a result of decreased prolifera-
tion, we proceeded with the 3[H]-thymidine in- 
corporation assay for 24 hours following siRNA-
transfection. VEGF-treatment increased OE33 
cell proliferation and served as positive control 
(Figure 3B). 3[H]-thymidine uptake was marked- 
ly decreased in DKK1-silenced OE33 cells in 
and one EJG-adenocarcinoma cell line (OE19) in resting conditions. C. Western blot analysis of DKK1 protein expres-
sion in all cell lines in resting conditions. β-Actin serves as a loading control. Significantly elevated amounts of DKK1 
were demonstrated in OE33 cells compared with the other cell lines (***P < .0001; one way anova).
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comparison with control cells or cells transfect-
ed with NT-siRNA (Figure 3B), indicating that 
DKK1-overexpression promotes cell prolifera-
tion in wild type OE33 cells. This notion was fur-
ther supported by a lower baseline proliferation 
feedback mechanism [15]. As shown by west-
ern blotting, DKK1-knockdown resulted in slig- 
ht stabilization of total β-catenin, suggesting 
potential downstream β-catenin signaling acti-
vation (Figure 4A). However, DKK1-knockdown 
Figure 2. DKK1 expression in OE33 cells following siRNA-mediated DKK1 
gene silencing: A. RT-PCR (a) and qRT-PCR (b) analysis of DKK1 mRNA ex-
pression. B. Western blot analysis of DKK1 protein expression. β-Actin serves 
as a loading control. C. ELISA of DKK1 protein concentration (pg/ml) in cell 
culture medium. D. Microscopy of Mock Control as well as NT-siRNA and 
DKK1-siRNA transfected OE33 cells, 96 h after siRNA-mediated DKK1 gene 
silencing (**P < .01; ***P < .0001; t test). E. qRT-PCR demonstrates the 
specific knockdown of DKK1 gene by DKK1-siRNA using GAPDH-siRNA as a 
positive and nontargeted siRNA as the negative controls.
of resting OE19 cells, which 
were found to express less 
DKK1, compared to that of 
resting OE33 cells as mea-
sured by 3[H]-thymidine incor-
poration assay for 24 and 48 
hours (Figure 3C). 
The impact of DKK1-knock- 
down on cell motility and 
invasion of OE33 cells was 
investigated next. As shown 
by transmigration and wound 
scratch assays respectively, 
DKK1-knockdown resulted in 
significant attenuation of cell 
invasion (Figure 3D) and cell 
migration (Figure 3Ea, 3Eb), 
suggesting that DKK1 pro-
motes the metastatic proper-
ties of OE33 cells.
Taken together, these find- 
ings signify that the high 
amounts of DKK1 expressed 
by OE33 cancer cells induce 
cell growth and migration in 
an autocrine loop, and as 




not regulate Wnt/β-catenin 
signaling negatively
To determine the tumor pro-
moting nature of DKK1, we 
tested next, how DKK1 regu-
lates tumor-associated signal-
ing pathways at the molecular 
level. We firstly focused on 
the oncogenic Wnt/β-catenin 
signaling. Given the previous-
ly reported downstream sig-
naling activation in OE33 cells 
[23] together with the DKK1-
upregulation, we wondered, 
whether DKK1 suppresses β- 
catenin transcriptional activi-
ty as expected in a negative 
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had no impact on GSK3β 
phosphorylation at Serine 9 
(Figure 4A), indicating absen- 
ce of additional GSK3β-inac- 
tivation, which would be ex- 
pected to enhance β-catenin 
de-phosphorylation. 
To examine, whether DKK1-
knockdown actually enhanc- 
Figure 3. DKK1 promotes prolif-
eration and migration in OE33 
cells: A. MTT assay in OE33 cells 
following siRNA-mediated DKK1 
gene silencing. Measurements 
were conducted 0, 48, 72, 96, 
120 and 144 hours after siRNA 
transfection in sixfold replicates. 
Values are means ± SE of 3 in-
dependent experiments and pre-
sented as percentage relative to 
time of treatment (0 h; 100%) (*P 
< .05; **P < .01; two way anova). 
B. 3H thymidine incorporation as-
say in OE33 cells following siRNA 
mediated DKK1 gene silencing. 
VEGF treatment serves as a posi-
tive control. Values are means ± 
SE of at least 3 replicates and 
presented as percentage of un-
treated controls (100%) (*P < 
.05). C. 3H thymidine incorpora-
tion assay in esophageal adeno-
carcinoma cells (OE33/OE19) in 
resting conditions with measure-
ments after 24 and 48 hours. 
Values are means ± SE of 3 rep-
licates and presented as percent-
age relative to baseline prolifera-
tion (0 h; 100%). OE33 cells show 
significantly elevated prolifera-
tion compared with OE19 cells 
both after 24 and 48 hours (*P 
< .05). D. Transmigration assay 
in OE33 cells following siRNA-
mediated DKK1 gene silencing. 
Values are means ± SE of 3 rep-
licates and presented as percent-
age of untreated controls (100%) 
(*P < .05). E. Wound healing as-
say in OE33 cells following siRNA-
mediated DKK1 gene silencing. 
(a) Measurements of the gap dis-
tance were conducted after 0, 6, 
12 and 24 hours via microscopic 
analysis. (b) Values are means ± 
SE of 6 independent experiments 
and presented as percentage re- 
lative to the initial gap distance 
(**P < .01; ***P < .001; two way 
anova).
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es the β-catenin signaling in 
response to the slight β-ca- 
tenin stabilization, we perfo- 
rmed a luciferase assay. The 
levels of TOP-flash activity, 
which reflect actual β-cate- 
nin signaling activity, did not 
alter following DKK1-knock- 
down (Figure 4B), suggesting 
that the DKK1-overexpress- 
ion exaggerates no inhibition 
on the downstream baseline 
β-catenin signaling in wild 
type OE33 cells. Accordingly, 
we investigated next, wheth- 
er a molecular defect of the 
endogenous DKK1 could jus-
tify this absence of inhibition. 
Therefore, we treated OE33 
cells with external, wild type, 
recombinant DKK1 protein 
(rhDKK1), seeking to observe 
downstream inhibition of β- 
catenin signaling. Instead, ex- 
ogenous rhDKK1 (500 ng/ml) 
for 24 hours onto OE33 cells 
had no effect on the baseline 
TOP-flash activity, as shown 
by luciferase assay (Figure 
4B). The treatment with lithi-
um chloride (LiCL), an estab-
lished chemical GSK3β-inhi- 
bitor, known to enhance Wnt/
β-catenin signaling, increased 
TOP-flash activity and served 
as positive control (Figure 
4B). In agreement with DK- 
K1-failure to attenuate β-ca- 
tenin signaling, DKK1-knock- 
down failed to alter the Cy- 
clin-D1- and AXIN2-mRNA lev-
els, the two main β-catenin 
target genes, as shown by 
qRT-PCR (Figure 4C).
In summary, these observa-
tions support that neither 
endogenous nor exogenous 
DKK1 can inhibit the down-
stream β-catenin signaling in 
OE33 cells, proposing a Wnt-
independent mechanism of 
DKK1-mediated tumor pro- 
motion. 
Figure 4. Wnt/β-Catenin signaling in OE33 cells following siRNA-mediated 
DKK1 gene silencing: A. Western blot analysis of DKK1, β-Catenin and 
pGSK3β/GSK3β protein expression. β-Actin serves as a loading control. Den-
sitometry graphs depict the means ± SE of 3 independent experiments. B. 
Luciferase assay (top) in OE33 cells following siRNA-mediated DKK1 gene 
silencing as well as stimulation with rhDKK1 (500 ng/ml) for 24 hours. LiCL-
treatment serves a s a positive control. C. qRT-PCR analysis of DKK1, AXIN 2 
and Cyclin-D1 mRNA expression following DKK1 gene silencing. ns: nonsig-
nificant (*P < .05; t test).
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DKK1 induces tumor growth via induction of 
Akt-phosphorylation
To enlighten the underlying molecular mecha-
nism of DKK1-mediated tumor growth, we 
examined next, how DKK1 affects common 
downstream oncogenic signaling pathways. As 
shwn by western blotting, DKK1-knockdown in 
OE33 cells significantly attenuated Akt-phosph- 
orylation at Ser 473, whereas the MAPK-pho- 
sphorylation remained unaffected (Figure 5A), 
supporting a distinct DKK1-mediated tumor 
promotion via Akt-phosphorylation. To further 
support, whether Akt mediates the role of 
DKK1, we treated serum-starved OE33 cells 
(1% FCS) with different concentrations of ex- 
ogenous rhDKK1 and showed that DKK1 sig-
nificantly increased AKT-phosphorylation in a 
dose-dependent manner (Figure 5B). Further- 
more, restoration of DKK1-protein levels after 
gene silencing by application of exogenous 
rhDKK1 (500 ng/ml for 4 hours) was able to 
rescue the AKT-phosphorylation, which was 
significantly attenuated by the elimination of 
endogenous DKK1 via siRNA gene silencing 
(Figure 5C). These findings support that AKT 
mediates the downstream signaling of DKK1 
and provide a mechanism to address the ob- 
served DKK1-mediated tumor progression. 
To elucidate whether Wnt-receptor interaction 
influences the DKK1-mediated Akt-activation, 
we subsequently determined the impact of 
Wnt3a-protein, the natural receptor-antagonist 
of DKK1, on the Aktser473-phosphorylation fol-
lowing DKK1-knockdown. Interestingly, the re- 
combinant Wnt3a (200 ng/ml rhWnt3a for 1 
h) increased Aktser437-phosphorylation only in 
OE33 cells following DKK1-Knockdown, and 
not in control NT-siRNA transfected cells (Fig- 
ure 5D). This finding proposes a Wnt3a-rece- 
ptor mediated downstream Akt-activation only 
in the absence of DKK1. To determine, whe- 
ther this Akt-activation comes along with a fur-
ther Wnt3a-driven β-catenin transcriptional 
activation, qRT-PCR of AXIN2 and Cyclin-D1 
was performed. As shown in Figure 5E, tran-
scription of both β-catenin target genes re- 
mained unchanged following Wnt3a-treatment 
even after DKK1-knockdown, suggesting that 
DKK1-knockdown did not sensitize cells to 
Wnt3a-mediated β-catenin activation. 
The impact of DKK1-knockdown on the epithe-
lial-mesenchymal transition (EMT) or the pro-
apoptotic pathways was further examined by 
western blotting in OE33 cells on key pathway 
proteins. The expression of E-Cadherin as well 
as that of Caspase 3, p53 and BCL-xl remained 
unaffected by DKK1-knockdown, underscoring 
that DKK1-mediated tumor promotion in EAC is 
not associated with EMT-induction or inhibition 
of pro-apoptotic agents (Figure 5F). 
In total, the above pieces of evidence under-
score that DKK1 promotes tumor growth in 
EAC via distinct downstream activation of Akt-
mediator, dependent of the receptor context 
and presence of canonical Wnts. 
Discussion
In this study, we defined that the specific Wnt-
antagonist, DKK1, which is highly expressed in 
EAC, functions as a tumor promoter via Akt-
phosphorylation and independently of Wnt-
axis. Human EAC-tissues were found to co-ex- 
press highly DKK1-protein along with elevated 
levels of transcriptionally active β-catenin in 
comparison to the corresponding healthy and 
premalignant esophageal tissues. To elucidate 
the function of DKK1, the OE33 adenocarcino-
ma cells, which overexpress DKK1, were sub-
jected to functional and molecular assays fol-
lowing siRNA-mediated DKK1-knockdown. At 
the functional level, OE33 cell viability, prolifer-
ation, migration and invasion were significantly 
attenuated by DKK1-silencing, suggesting that 
DKK1-overexpression induces tumor growth 
and survival. In favor of this notion, OE19 cells, 
which express less DKK1-protein, demonstrat-
ed lower proliferation rates. At the molecular 
level, neither DKK1-knockdown nor exogenous 
rhDKK1 were able to regulate the baseline 
β-catenin signaling in OE33 cells, suggesting 
that β-catenin transcriptional activity is inde-
pendent of the DKK1 site-of-action. The tumor 
inducing properties of DKK1 were further inves-
tigated in conjunction with downstream onco-
genic pathways. Here, DKK1-knockdown was 
found to significantly inhibit Akt-phosphoryla- 
tion downstream, whereas MAPK-phosphoryla- 
tion and the expression of EMT-Marker, E-Cad- 
herin or pro-apoptotic agents remained unch- 
anged, signifying a rather distinct Akt-medi- 
ated downstream mechanism for the DKK1-
dependent tumor promotion. Intriguingly, the 
Wnt-agonist, Wnt3a, restored the Akt-phorph- 
orylation only in absence of DKK1, without 
however being able to further stimulate β-ca- 
tenin signaling. These findings define DKK1 as 
a tumor promoter in EAC and subsequently 
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underscore its significance as well as that of its 
receptor as a potential therapeutic target in 
EAC. 
The need to investigate the exact role of DKK1 
was prompted by its aberrant upregulation in 
EAC compared to the premalignant esophageal 
specimens [23]. Given that DKK1 is an estab-
lished direct target-gene of β-catenin, the repo- 
rted activation of the canonical Wnt/β-catenin 
signaling in EAC could justify the DKK1-upre- 
gulation [15, 16]. However, induction of DKK1-
transcription independently of Wnt-axis has 
also been reported in other malignancies and 
could apply in EAC as well [27]. Nevertheless, 
the simultaneous co-expression of high levels 
of DKK1-protein together with elevated levels 
of transcriptional active β-catenin in EAC-tissu- 
es favors the β-catenin-driven DKK1-upregula- 
tion. Yet, this notion raises questions on the 
role of DKK1 upon Wnt-signaling, as an estab-
lished specific Wnt-antagonist functioning in a 
negative feedback-loop [16]. As such, the ex- 
cess secretion of DKK1-protein in EAC should 
have been expected to suppress the Wnt-sig- 
naling in return. However, as we show here, 
DKK1 failed to impact the β-catenin signal- 
ing. Neither DKK1-knockdown nor exogenous 
rhDKK1 could regulate the β-catenin transcrip-
tional activity in vitro. These findings become 
highly important, given our previous report, 
which demonstrated DKK1-induced suppres-
sion of Wnt/β-catenin singaling in Barrett-me- 
taplastic cells, suggesting that a possible early 
perturbation of the DKK1-mediated signaling 
suppression may trigger dysplasia and further 
EAC-tumorigenesis [23]. Why DKK1 fails to 
inhibit β-catenin signaling in OE33 cells simi-
larly to BE-metaplastic cells, can possibly be 
explained either by (a) a defective negative 
feedback loop, caused by post-transcriptional 
DKK1 loss-of-function or by (b) an aberrant sig-
naling activation downstream of the DKK1 site-
of-action. Intriguingly, the inability of the rhWn-
t3a to stimulate β-catenin signaling activity, 
even following DKK1-silencing, allow us the 
assumption, that the aberrant oncogenic β- 
catenin signaling in EAC is independent of the 
Wnt-axis and is triggered downstream of the 
DKK1/Wnt3a site-of-action, the LRP6-receptor 
[28]. In the light of these findings, it may not be 
a perturbation of DKK1-function that prevents 
Figure 5. Expression analysis of molecular regulators of tumor growth in OE33 cells following siRNA-mediated DKK1 
gene silencing and stimulation with rhDKK1 or rhWnt3a: (A) Western blot analysis of DKK1, pAkt/Akt and pERK/
ERK protein expression in OE33 cells following siRNA-mediated DKK1 gene silencing. (B) Western blot analysis of 
pAkt/Akt protein expression in OE33 cells following serum starvation (1% FCS) followed by stimulation with different 
concen trations of rhDKK1 for 24 hours. Cells incubated with 10% FCS served as positive control. (C) Western blot 
analysis of DKK1 and pAkt/Akt protein expression in OE33 cells following siRNA-mediated DKK1 gene silencing and 
subse quent treatment with 500 ng/ml rhDKK1 for 4 hours. The cells stimulated with rhDKK1 demonstrated an ex-
tra band by 29 kDa of DKK1 protein, which depicts the intracellular trans-localization of the rhDKK1 protein, which 
has not been subjected to further post-translationally modification as in case of the endogenous DKK1 protein (37 
kDa). On the very right panel, only rhDKK1 protein was loaded in order to confirm the molecular weight. (D) Western 
blot analysis of pAkt/Akt protein expression in OE33 cells following siRNA-mediated DKK1 gene silencing and treat-
ment with 200 ng/ml rhWnt3a for 1 hour. (E) qRT-PCR analysis of DKK1, Axin2 and Cyclin-D1 mRNA expression in 
OE33 cells following siRNA-mediated DKK1 gene silencing and subsequent treatment with 200 ng/ml rhWnt3a for 
4 hours. (F) Western blot analysis of E-Cadherin, Bcl-xL, p53 and Caspase 3 protein expression in OE33 cells follow-
ing siRNA-mediated DKK1 gene silencing. β-Actin serves as a loading control (*P < .05; t test). Densitometry graphs 
depict the means ± SE of 3 independent experiments.
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Wnt-axis inhibition, but a rather, still unclear, 
neoplastic “switch on” of aberrant β-catenin 
transcriptional activation, downstream of DKK1 
site-of-action. In favor, emerging evidence sup-
ports that more than one mechanism, also 
independent of Wnts, can induce the oncogenic 
β-catenin signaling activation towards tumor 
formation [29]. For example, tumor cells over-
expressing EGF-receptor, as in case of OE33 
cells [30], could display GSK-3β-independent 
activation of β-catenin signaling in response to 
EGF stimulation, without changes on β-catenin’s 
stability or phosphorylation levels [31]. Undoub- 
tedly, similar growth factor-based mechanisms 
may underlay the aberrant β-catenin signaling 
seen in EAC and merit further clarification. 
Enhanced DKK1-transcription elevates the am- 
ounts of the secretory protein, which antago-
nizes the oncogenic Wnt-signals by binding to 
the Wnt co-receptor LRP6, resulting to its inter-
nalization [28]. As such, DKK1 is mostly expect-
ed to act as a tumor suppressor. Indeed, DKK1 
has been found downregulated in colorectal 
cancer and melanoma due to epigenetic inacti-
vation (DNA-hypermethylation), while its loss-
of-expression has been strongly correlated with 
advanced stages of carcinogenesis [15, 18, 
32]. Accordingly, several reports have shown 
that DKK1 inhibits growth in various cancer cell 
lines, while it can also induce or increase sensi-
tivity of cancer cells to apoptosis (summarized 
in [33]), supporting a role as tumor suppressor. 
However, several parallel reports have also 
defined a role for DKK1 as a tumor promoter. In 
various carcinomas including lung, prostate, 
pancreas and breast cancers, DKK1-express- 
ion has been found significantly elevated, while 
high DKK1-secretion has been associated with 
cancer progression [33]. In line with the latter, 
we defined an oncogenic role for DKK1 in EAC, 
based on (a) its overexpression in EAC malig-
nant tissues, (b) its failure to suppress the 
downstream oncogenic β-catenin signaling ac- 
tivity and mainly (c) the observed attenuation of 
cell growth, metastasis and invasion of OE33 
cells following DKK1-silencing in vitro. Similar 
DKK1-dependent cancer promotion has been 
proposed in different malignancies, which also 
originate from foregut-derivatives. For example, 
induced DKK1-expression increased the prolif-
eration rate and invasion of squamous esopha-
geal cancer cells [34], while its overexpression 
has been associated with tumor aggressive-
ness and chemotherapy-refractory phenotype 
in non-small cell lung cancer cells [35]. Notably, 
lymph node metastasis in EAC were recently 
reported to correlate with high DKK1-express- 
ion in the loco-regional lymph nodes of the pri-
mary tumor [24], suggesting that tumor DKK1-
secretion may orchestrate the lymphatic meta- 
stasis in EAC. These observations together with 
our current findings point to a significant onco-
genic role of DKK1 in EAC. 
Although the molecular impact of DKK1 has 
been mainly examined in the context of Wnt-
signaling [16], the evidence presented here 
suggests that DKK1-dependent cancer pro-
gression in EAC is independent of Wnt-axis. 
Therefore, the oncogenic function of DKK1 may 
require binding to a putative receptor along 
with activation of distinct downstream signaling 
cascades. Increased activity of growth factor-
regulated kinases, up-regulated expression of 
anti-apoptotic proteins and endothelial-mesen-
chymal transition are reported to contribute to 
the EAC tumor phenotype [36] and were the 
subject of further investigation following DKK1-
knockdown. A significant attenuation of Akt-
phosphorylation was revealed following DKK1 
loss-of-expression, while MAPK-kinases and 
pro-apoptotic or EMT-markers remained unaf-
fected. Given that aberrant activation of PI3K/
Akt pathway is an important driver of neoplas- 
tic progression [37], the inactivation of serine/
threonine protein kinase Akt in OE33 cells fol-
lowing DKK1-knockdown justifies the detected 
phenotypical changes. Phospho-Akt, an indica-
tor of active Akt-signaling, increases along the 
progression from normal esophagus to BE, dys-
plasia, and EAC and its overexpression has 
been associated with tumor progression and 
poor prognosis [38, 39]. However, this is likely 
due to increased upstream signaling, since ac- 
tivating mutations in Akt have not been report-
ed in EAC [40]. Thus, DKK1-protein appears as 
a novel trigger of Akt-activation in EAC, with, 
however, still unclear mediator-receptor. Rece- 
ntly, the cytoskeleton-associated protein 4 (CK- 
AP4) has been recognized as a novel receptor 
for DKK1 [27, 41], providing new insights in 
DKK1-dependent cancer promotion. DKK1-
CKAP4 interaction is reported to activate Akt 
through phosphatidylinositol 3-kinase (PI3K) 
and as such to induce cellular proliferation [27]. 
Simultaneous overexpression of both, DKK1 
and CKAP4, has been reported in pancreatic 
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and lung tumors accompanied by a poor prog-
nosis [27], while DKK1-CKAP4 interaction in- 
duced proliferation of squamous esophageal 
cancer cells via Akt-activity [42]. Accordingly, 
the DKK1-CKAP4-Akt cascade appears attrac-
tive to present a novel signaling pathway for 
EAC tumor progression and is currently under 
investigation in our laboratory. 
The rescue of Akt-phosphorylation by rhWnt3a, 
only in the absence of DKK1-protein, proposes 
a cross-talk between Wnt-axis and downstream 
Akt-phosphorylation. In support, Wnt3a has be- 
en reported to rapidly activate Wnt/β-catenin 
signaling and to promote Akt-phosphorylation 
via IRS/PI3K signaling in pancreatic NIT-1 beta 
cells, with these effects to be completely abro-
gated by DKK1 [43]. In our report, following 
DKK1-elimination, Wnt3a restored Akt-phosph- 
orylation but failed to activate the actual down-
stream β-catenin signaling. These observations 
verify, on one hand, the Wnt-independent na- 
ture of the aberrant β-catenin signaling in EAC, 
but also, on the other hand, highlight an inter-
esting downstream cross-talk between the Wnt 
and DKK1 common site-of-action, the LRP6-
receptor, and downstream oncogenic signaling 
cascades. As such, the exact function of DKK1 
in cancer progression may also be dictated by 
the context of Wnt-ligands in tumor microenvi-
ronment and the receptor’s context of prema-
lignant and malignant cells. In the absence of 
Wnt-ligands and upon expression of oncogenic 
receptors, such as CKAP4, DKK1 acts as a tu- 
mor promoter, while in the presence of Wnt-lig- 
cance of such DKK1-mediated Wnt-inhibition, 
without, however, an actual suppression of β- 
catenin signaling, requires further investigation 
in accordance with the, rather still unclear, pre- 
sence of canonical Wnts in EAC tumor microen- 
vironment.
An acknowledged limitation of our study is that 
the conclusions are based mostly on an in vitro 
model. However, the mechanistic approach uti-
lized here, with functional and molecular assays 
following DKK1-knockdown in OE33 cells, un- 
covers a clear oncogenic role for DKK1, while it 
provides a sufficient interpretation of the, so 
far unexplained, DKK1-overexpression in EAC. 
Undoubtedly, the DKK1-failure to inhibit β-cate- 
nin signaling in combination with the induction 
of Akt-phorphorylation in those cells, justify the 
observed phenotypical changes indicative of 
tumor progression. Then again, it remains to be 
clarified, whether DKK1 promotes tumor growth 
also in vivo. Such studies could be performed 
using EAC patient-derived xenografts in mice. 
Possible correlations of tissue DKK1-express- 
ion or serum DKK1-levels with the tumor-sta- 
ge in EAC-patients along with their predictive 
value are not addressed in this study. However, 
in malignancies like hepatocellular carcinoma 
and prostate cancer, in which DKK1-knockdown 
inhibited cell proliferation and migration in vitro 
assays [44, 45], metastatic sites demonstrat-
ed higher DKK1-expression in comparison with 
that of the primary tumors, and high DKK1-
levels of tumor tissue and in blood serum were 
predictive for shorter overall survival [46, 47]. 
Figure 6. Schematic illustration of DKK1-
mediated signaling and tumor progression 
in esophageal adenocarcinoma.
ands and the absence of on- 
cogenic receptors it can act 
as a tumor suppressor, as 
previously reported in Barrett-
metaplastic cells via inhibi-
tion of Wnt-axis [23]. Thus, 
our current model supports 
that DKK1-upregulation in 
EAC promotes tumor growth 
through distinct Akt-phospho- 
rylation, highly likely by bind-
ing to a primitive receptor, 
possibly the CKAP4, while at 
the same time, maintains its 
ability to block Wnt-ligand-
receptor interactions, and, as 
such, to abrogate downstre- 
am oncogenic cross-activa-
tions (Figure 6). The signifi-
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Particularly, in squamous esophageal cells EC- 
9706, a vector-induced DKK1-overexpression 
promoted cell growth and invasion in vitro [34], 
while DKK1-positive tumors were found to have 
poorer disease-free-survival (DFS) than those 
with negative tumors [48]. Similarly, based on 
the DKK1-driven tumor progression seen in OE- 
33 cells, the prognostic significance of DKK1-
overexpression should be also anticipated in 
EAC-patients; however, the clinical relevance 
of DKK1 in EAC still remains ambiguous and 
needs to be proven. 
In conclusion, in this study we define for the 
first time an oncogenic role for DKK1 in EAC. 
We attribute this DKK1-dependent tumor pro-
gression to a rather Wnt-independent mecha-
nism, which involves distinct downstream Akt-
activation. Given that β-catenin signaling was 
neither attenuated by DKK1 nor further elevat-
ed by Wnt3a in OE33 cells even following DKK1-
silencing, signifies that the aberrant β-catenin 
transcriptional activity in EAC is triggered by 
growth factors, independently of Wnt-axis. This 
activation subsequently results in DKK1-over- 
expression, which, in return, can promote tumor 
growth and metastasis, based on the context 
of Wnt-ligands and specific receptors. These 
novel findings underscore the significance of 
DKK1 in EAC tumor biology and point to its pos-
sible usefulness as prognostic marker or novel 
therapeutic target for future tailored therapies 
for this malignancy. 
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Supplementary Figure 1. Western blot analysis of DKK1 protein expression in OE33 cells following siRNA-mediated 
DKK1 gene silencing, (A) 96 hours and (B) 144 hours after siRNA transfection. β-Actin serves as a loading control.
